News | September 27, 2010

FDA Gives Favorable Votes to Digital Mammography Tomosynthesis System

September 27, 2010 — The Radiological Devices Panel of the U.S. Food and Drug Administration (FDA) unanimously voted that Hologic Inc.’s pre-market approval (PMA) demonstrated both the effectiveness and safety of the company’s Selenia Dimensions 3-D digital mammography tomosynthesis system. The panel also voted in favor that the benefits of this new technology outweigh the risks.

Following the panel meeting, Hologic will work with the FDA on next steps for approval of its 3-D digital mammography system. While the panel’s favorable vote is advisory in nature, the FDA will consider it in its final review of Hologic’s PMA application for the Selenia Dimensions tomosynthesis system.

“Our Selenia Dimensions 3-D technology marks tremendous progress in the early diagnosis of breast cancer,” said Jay A. Stein, cofounder and chief technical officer. “The system is designed to increase accuracy when screening women for the presence of cancerous tissue and to enable a more precise characterization of suspicious lesions. I speak for all of Hologic in voicing great satisfaction that the FDA panel has weighed in so positively in favor of this valuable new tool in the battle to limit breast cancer mortality.”

Selenia Dimensions 3-D digital mammography tomosynthesis system is a new method for breast cancer screening and diagnosis. Unlike current mammography systems, which generate a 2-D image, breast tomosynthesis produces a 3-D image. Hologic says it believes its multicenter clinical study has demonstrated that compared to 2-D digital mammography alone, 3-D digital tomosynthesis used in combination with 2-D digital mammography has the potential to reduce recall rates and improve cancer detection.

Selenia Dimensions 3-D digital mammography tomosynthesis system is presently commercially available outside the United States, including countries in Europe, Latin America and Asia. In North America, commercial systems are installed in Canada and Mexico. In the United States, Selenia Dimensions is currently available as a 2-D only system that can be upgraded to do breast tomosynthesis (3-D) imaging when and if the product is approved by the FDA.

Related Content

Podcast | Cybersecurity | June 24, 2019
Medical imaging is ripe for the picking. Here’s why.
TeraRecon Receives FDA Clearance for Northstar AI Results Explorer
Technology | Artificial Intelligence | June 20, 2019
Advanced visualization and artificial intelligence (AI) technology provider TeraRecon has successfully completed a U.S...
Third FDA Clearance Announced for Zebra-Med's AI Solution for Brain Bleed Alerts
Technology | Artificial Intelligence | June 19, 2019
Zebra Medical Vision announced it has received its third U.S. Food and Drug Administration (FDA) 510(k) clearance for...
Washington Open MRI Chooses RamSoft’s PowerServer RIS/PACS
News | PACS | June 18, 2019
Washington Open MRI (WOMRI) has selected RamSoft’s PowerServer RIS/PACS (radiology information system/picture archiving...
Double Black Imaging Announces Expanded Display Line and Ergonomic Workstation Solutions

The DBI CL8MPS from Double Black Imaging

News | Flat Panel Displays | June 18, 2019
Double Black Imaging (DBI) and their Image Systems Division are releasing their new clinical and diagnostic display...
Canon Medical Receives FDA Clearance for AiCE Reconstruction Technology for CT
Technology | Computed Tomography (CT) | June 18, 2019
Canon Medical Systems USA Inc. has received 510(k) clearance on its new deep convolutional neural network (DCNN) image...
Warm Springs Health & Wellness Center Implements Digisonics Solution for OB Ultrasound
News | Ultrasound Women's Health | June 17, 2019
Warm Springs Health & Wellness Center in Warm Springs, Ore., has selected the Digisonics OB PACS (picture archiving...
Konica Minolta Healthcare Introduces New Financing Services Program for Exa Enterprise Imaging
News | Enterprise Imaging | June 17, 2019
June 17, 2019 – Konica Minolta Healthcare Americas Inc.
Fujifilm Announces Nationwide Breast Health Campaign With Mobile Mammography Coach

At the center of the campaign, Fujifilm will be traveling around the U.S. with its "Aspire to Be Fearless" mobile mammography coach to provide educational opportunities for clinicians, raise awareness about the importance of screening and will be providing mammograms to the underserved population in key locations.

News | Mammography | June 14, 2019
Fujifilm Medical Systems U.S.A. Inc. announced a nationwide awareness campaign titled ‘Aspire to Be Fearless’ focused...